康诺亚-B(02162.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-Gastric01取得积极顶线结果

智通财经07-28

【康诺亚-B(02162.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-Gastric01取得积极顶线结果】智通财经APP讯，康诺亚-B(02162.HK)发布公告，有关集团与AstraZeneca AB (AstraZeneca，一家全球生物制药公司)合作的CMG901(亦称为sonesitatug vedotin，AZD0901)最新临床进展。CLARITY-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2654078357?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-28 12:10","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2654078357","market":"hk","top_or_hot":-1,"title":"康诺亚-B(02162.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-Gastric01取得积极顶线结果","media":"智通财经","content":"<div>\n<p>【康诺亚-B(02162.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-Gastric01取得积极顶线结果】智通财经APP讯，康诺亚-B(02162.HK)发布公告，有关集团与AstraZeneca AB \n\n(AstraZeneca，一家全球生物制药公司)合作的CMG901(亦称为sonesitatug vedotin，AZD0901)最新临床进展。CLARITY-...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康诺亚-B(02162.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-Gastric01取得积极顶线结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康诺亚-B(02162.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-Gastric01取得积极顶线结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-28 12:10 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【康诺亚-B(02162.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-Gastric01取得积极顶线结果】智通财经APP讯，康诺亚-B(02162.HK)发布公告，有关集团与AstraZeneca AB \n\n(AstraZeneca，一家全球生物制药公司)合作的CMG901(亦称为sonesitatug vedotin，AZD0901)最新临床进展。CLARITY-...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2654078357","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654078357","pubTimestamp":1785211808,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【康诺亚-B(02162.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-Gastric01取得积极顶线结果】智通财经APP讯，康诺亚-B(02162.HK)发布公告，有关集","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1587":"次新股","BK1161":"生物科技","BK1574":"生物医药B类股","02162":"康诺亚-B","BK1583":"高瓴概念"},"translate_title":"Connoya-B (02162.HK): CMG901 (AZD0901) Global Phase III Clinical Trial CLARITY-Gastric01 Achieves Positive Top-Line Results","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1.5},"content_text":"【康诺亚-B(02162.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-Gastric01取得积极顶线结果】智通财经APP讯，康诺亚-B(02162.HK)发布公告，有关集团与AstraZeneca AB \n\n(AstraZeneca，一家全球生物制药公司)合作的CMG901(亦称为sonesitatug vedotin，AZD0901)最新临床进展。CLARITY-Gastric01全球III期临床试验公布的积极顶线结果显示，与研究者选择的治疗方案相比，CMG901(sonesitatug \n\nvedotin，AZD0901)在二线及后线 Claudin \n\n18.2(CLDN18.2)阳性晚期胃癌患者中展现出具有统计学显著性且极具临床意义的总生存期(OS)改善。该试验纳入了局部晚期或转移性胃癌、胃食管结合部(GEJ)癌或食管腺癌(EAC)患者，入组标准为任意染色强度下至少25%的肿瘤细胞表达CLDN18.2。据估计，约60%的胃癌╱GEJ癌在≥25%的肿瘤细胞中表达 \n\nCLDN18.2。在美国、欧盟、中国和日本，每年约有18.35万名患者因CLDN18.2 \n\n阳性、HER2阴性的晚期或转移性胃癌╱GEJ癌接受二线及后线治疗。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654078357","isCrawlerRequest":true}